OMNIAB, INC. Accrued Liabilities, Current
OMNIAB, INC. (OABI) had Accrued Liabilities, Current of $4.50 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $4.50M.
- 2026-03-31: Accrued Liabilities, Current $4.03M.
- 2025-12-31: Accrued Liabilities, Current $6.29M.
- 2025-09-30: Accrued Liabilities, Current $5.15M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $4.50M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $4.03M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $6.29M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $5.15M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $4.71M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $3.58M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $6.14M 10-K · filed 2026-03-04 |
| 2024-09-30 | $5.45M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $4.55M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $4.03M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $7.07M 10-K · filed 2025-03-18 |
| 2023-09-30 | $6.52M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.93M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $3.91M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $5.56M 10-K · filed 2024-03-25 |
| 2022-11-01 | $25.00K 10-K · filed 2024-03-25 |
| 2021-12-31 | $3.75M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |